Loading
Distinct shells carrying a filed role for this person — not every shell they have ever touched.
Of those vehicles, the ones that closed a merger.
Announced but not closed, and still hunting.
No closed vehicle here has both a stored price and a filed trust value to score it against.
1 vehicle on file, newest listing first
none appears on more than one
Syed T. Husain currently serves as Chairman and Chief Executive Officer of Made Scientific, a cell therapy contract development and manufacturing organization (CDMO) headquartered in Princeton, New Jersey, and backed by South Korea's GC Corporation. In September 2024, he was appointed CEO and board member of BioCentriq, the predecessor entity, and subsequently relaunched the company under the Made Scientific banner in 2025, with the name standing for Manufacturing and Development Excellence. Under his leadership, the company operates a purpose-built 60,000-square-foot GMP facility equipped with ISO 7 cleanrooms, BSL-2 compliance to FDA and EU Annex 1 standards, and capabilities spanning both autologous and allogeneic cell therapy manufacturing in open and closed processing systems. A 12,000-square-foot expansion announced in April 2026 is expected to add approximately 5,000 manufacturing batches per year at full capacity, with FDA licensure targeted for the first quarter of 2027. Husain also serves as a director on the Made Scientific board, which includes Ted Dolan, Yonghoon Kim, Soyoung Park, Jin Pyun, and Harry S. Rathore, Ph.D., and he holds a SPAC role as LTGR at Long Table Growth.
Husain brings over twenty years of experience across the CDMO and biopharmaceutical manufacturing spectrum. Prior to his current role, he served as Chief Commercial Officer at Resilience, where he built a commercial organization spanning cell and gene therapies, biologics, vaccines, and nucleic acids, and established a multi-billion-dollar opportunity pipeline through strategic partnerships with top pharmaceutical and biotech companies. Before Resilience, he held CDMO leadership positions at Emergent BioSolutions, Alcami Corporation, and Lonza, sharpening his expertise in commercial strategy and operations. He began his career in manufacturing compliance at Wyeth before advancing through validation, product development, and manufacturing leadership roles at Pfizer. His track record includes guiding organizations through transformative growth, go-to-market innovation, and industry disruption, with a particular focus on bridging the gap between clinical development and commercial-scale manufacturing for breakthrough cell therapies.
Husain holds a Master of Business Administration from Cornell University's Johnson Graduate School of Management and a Bachelor of Science in Chemical Engineering from the New Jersey Institute of Technology (NJIT), where he serves on the Industrial Advisory Board for the Otto H. York Department of Chemical Engineering. His industry leadership extends to chairing the Education Committee and serving on the Advisory Council for the Drug, Chemical & Associated Technologies Association, alongside active involvement in the Biotechnology Innovation Organization (BIO), the Society of Biological Engineers, the American Institute of Chemical Engineers, and the American Chemical Society. Based in the New York metropolitan area, Husain is known for challenging industry assumptions and pushing past conventional approaches to create a CDMO model that prioritizes manufacturing readiness early in the development lifecycle, accelerating scalability and flexibility for groundbreaking therapies.
This record is keyed to SEC CIK 0002114021 — the identifier this person files under in their own name. Every vehicle above is a filing made under that CIK, so “the same person on two shells” is a fact about an SEC identifier rather than about a name that happens to match.
Roles are the strings the filings used, in the order they were filed. Nothing on this page ranks them, infers seniority, or offers a reason why any two of these names recur — a recurrence is a count, and the filings that produced it are linked beside every row. We also hold 5 institutional-holder rows on these vehicles, under 5 distinct name strings, and none of them is counted across vehicles: that table has no CIK column, and matching holders by name would merge firms that are not the same firm.